Aspire-Lakewood (ASBP) vs Chemomab Therapeutics (CMMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aspire-Lakewood (ASBP) has outperformed Chemomab Therapeutics (CMMB) over the past year, gaining 83.8% versus a loss of 53.0%. Aspire-Lakewood is the larger company by market cap ($10.0 million vs $9.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | CMMB |
|---|---|---|
| Share price | $7.13 | $1.19 |
| Market cap | $10.00M | $9.58M |
| 1-day change | -5.44% | +4.39% |
| YTD return | +35.04% | -27.88% |
| 1-year return | +83.76% | -52.96% |
| 5-year return | — | -96.65% |
| EPS (TTM) | $-30.89 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.20K | — |
| Net income (latest FY) | $-24.48M | $-8.99M |
| Gross margin | -1.87% | — |
| Operating margin | -312016.95% | — |
| Net margin | -394725.06% | — |
| 52-week high | $9.50 | $2.99 |
| 52-week low | $0.11 | $0.92 |
| Distance from 52-week high | -24.95% | -60.20% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +320.17% |
| Average volume | 29.24K | 102.39K |
| Shares outstanding | 1.40M | 8.05M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASBP has outperformed CMMB by 136.7 percentage points over the past year.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Health Care · Biotechnology: Pharmaceutical Preparations
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations
ASBP vs CMMB FAQ
Which is bigger, Aspire-Lakewood or Chemomab Therapeutics?
Aspire-Lakewood (ASBP) is larger, with a market capitalization of $10.00M compared with $9.58M for Chemomab Therapeutics (CMMB).
Which stock has performed better over the past year, ASBP or CMMB?
ASBP returned +83.76% over the past 12 months, compared with -52.96% for CMMB (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and Chemomab Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.